Bayer HealthCare / Facts & Figures

Facts & Figures

Science for a better life - Medical Progress for the Benefit of the Patient

From world-renowned pharmaceutical products to high-tech platforms, from innovative diagnostics technologies to veterinary medicines – Bayer HealthCare is a globally researching healthcare company and develops products of the divisions Animal Health, Pharmaceuticals, Consumer Care and Medical Care.

Facts and Figures at a glance



Research expenses 2013 2.040 € million (2012: 1.955 € million)
Proportion of total Bayer group research expenses 2013 63,9%
Employees in Research & Development 7,800
Main research locations Berlin and Wuppertal, Germany, Berkeley, USA, Bejing, CHina
Research focus
  • Berlin:
    Diagnostic Imaging, Oncology, Women’s Healthcare
  • Wuppertal:
    Hematology, Cardiology
  • Berkeley:
    Biologics
  • Bejing:
    R&D Hub Asia

Research activities 2013

In 2013 we spent €2,040 million (2012: €1,955 million) for research and development in the Pharmaceuticals and Consumer Health segments. This amounted to 63.9% of R&D spending in the Bayer Group and was equivalent to 10.8% (2012: 10.5%) of HealthCare sales. At the end of 2013, some 7,800 employees of HealthCare were working in research and development.

Research and development expenses in the Pharmaceuticals segment amounted to €1,654 million (2012: €1,561 million), or 14.8% (2012: 14.5%) of segment sales. Drug discovery in the Pharmaceuticals segment focuses on the areas of cardiology, oncology, gynecological disorders and hematology. Complementing this work is common mechanism research in areas such as ophthalmology and inflammation. We conduct research activities at four centers, of which two are located in Germany and two in the United States. Work in Berlin and Wuppertal, Germany, mainly focuses on the discovery, optimization and development of new active substances. Research is also carried out at these sites in the fields of drug metabolism, pharmacokinetics, toxicology and clinical pharmacology. Our research and development activities in the Mission Bay district of San Francisco and in Berkeley, California, United States, are concentrated on biologicals and hematology. We also operate innovation centers in Beijing, China, and Singapore, through which we coordinate our research partnerships in Asia.

We conducted clinical trials with several drug candidates from our research and development pipeline during 2013 to drive the development of new substances for treating diseases with a high unmet medical need. Following the completion of the required studies with a number of these drug candidates, we submitted applications to one or more regulatory agencies for approvals or approval expansions.

We have recently launched five innovative medicines on the market. Of special importance is our anticoagulant Xarelto™ (active ingredient: rivaroxaban). In the area of oncology, Stivarga™ (active ingredient: regorafenib) is approved for the treatment of advanced colorectal cancer and gastrointestinal stromal ¬tumors (GIST) in some countries, and approvals are pending in others. In 2013 we received marketing authorization for Xofigo™ (active ingredient: radium-223 dichloride) in the treatment of bone metastases in prostate cancer patients. Other promising products recently launched include ¬Eylea™ (active ingredient: aflibercept) to treat various eye diseases. Riociguat, a new substance to treat different forms of ¬pulmonary hypertension, was approved in the U.S. and Japan in 2013 under the trade name Adempas™. In addition, we strengthen our products through life-cycle management to improve their value for patients and/or expand their indications.

Research locations

Research activities and capacities are bundled in Germany at the sites in Berlin and Wuppertal, and in the United States in the Mission Bay neighborhood of San Francisco and at Berkeley, California. Work in Berlin and Wuppertal mainly focuses on the discovery, optimization and development of new active substances. Research is also carried out at these sites in the fields of drug metabolism, pharmaco kinetics, toxicology and clinical pharmacology. Our research and development activities in Mission Bay and Berkeley are concentrated on biologicals and hematology. We also operate an innovation center in Beijing, China.

Contact Research & Development

 
Search
Bayer HealthCare Links

Bayer scientific magazine
Clinical trials

Information about clinical studies is available at database of


http://healthcare.bayer.de/scripts/pages/en/research_development/facts_amp_figures/index.php

Copyright © Bayer HealthCare AG